Surfing The NASH Tsunami Podcast

Drug developers, investors, researchers, and corporate executives wrestle weekly to understand what is happening in commercial development of NASH medications. Hepatology researcher and Key Opinion Leader Stephen Harrison, M.D., C-suite veteran Peter Traber, M.D., and Forecasting and pricing guru Roger Green, M.B.A. discuss the issues affecting the evolving NASH market from their own unique perspectives on the Surfing the NASH Tsunami podcast.

Newest Episode…

We record each week and answer your questions along with our focussed topics. To have your question answered in future episodes… 

Sign Up For Email Notifications when the next episode is available!

Subscribe for free. New podcasts drop Thursday.

We record each week and answer your questions along with our focussed topics. To have your question answered in the episode, ask your question no later than Tuesday afternoon by 2pm. You can also Tweet @HEPdyamics

New Hope, PA – April 13, 2020, Hep Dynamics LLC

Surfing The NASH Tsunami Podcast

Hep Dynamics LLC announces the launch of a new podcast series. “Surfing the NASH Tsunami”, (, focused on challenges, solutions and news in NASH drug development. This podcast is geared toward NASH investigators and clinicians, C-suite and R&D executives at drug and diagnostic developers and the investment community.

HEP DYNAMICS Launches New Podcast Series: “Surfing the NASH Tsunami”  Hosted By:

Hepatology Researcher and KOL
Stephen Harrison, MD

C-Suite Veteran
Peter Traber

Forecasting and Pricing Guru
Roger Green

Dr. Stephen Harrison says, “We are excited about this podcast series and the impact it will make in advancing innovation in NASH drug and diagnostic development.” Roger Green adds, “Clients have asked for a place where stakeholders with different perspectives can examine the issues facing the NASH market. Yas, Stephen, Peter and I have developed this series to address their need.”

A key element in Surfing the NASH Tsunami is that each session will begin by discussing questions listeners have sent us after the previous session. Send questions or provide feedback and ideas for the podcast, contact us via Ask A Question form below or  Twitter.

To listen to the podcast, visit

Surf’s up!

[fusebox_track_player_latest url=”” background=”#ffffff” download=”false” social=”false” ]

New Pod City

Ask Our Panelists A Question…

Dr. Harrison earned his medical degree from the University of Mississippi School of Medicine. He completed his internal medicine residency and gastroenterology fellowship at Brooke Army Medical Center and a 4th year advanced liver disease fellowship at Saint Louis University. He is board certified in both Internal Medicine and Gastroenterology. Dr. Harrison is currently a Visiting Professor of Hepatology at the Radcliffe Department of Medicine, University of Oxford. He is internationally known for studies in hepatitis C and non-alcoholic fatty liver disease with over 200 peer reviewed publications in these fields. Currently, Dr. Harrison currently serves as the Medical Director for Pinnacle Clinical Research and the President of Summit Clinical Research.
Dr Peter Traber is a gastroenterologist/hepatologist physician
Peter G. Traber, MD President, PGT Life Sciences Consulting

Dr Peter Traber is a gastroenterologist/hepatologist physician executive with a distinguished career of over 30 years in drug development, life sciences research, management, and governance, with demonstrated success in large matrix and small organizations, including those in the pharmaceutical industry, biotechnology, academia, and healthcare. As an industry advisor, he helps identify solutions for biopharmaceutical clients with strategic and drug development challenges, focused on liver, gastrointestinal, inflammatory and fibrotic diseases.

Roger Green serves as CEO at RG+A, Inc., Managing Principal of Hep Dynamics LLC and Managing Director of Go To Market Advisors, LLC.

RG+A, founded in 1991, provides Market Research, forecasting and strategic support services to biopharmaceutical, medical device and diagnostics companies. In recent years, RG+A has worked with translational diagnostics companies and digital AI firms on market development and education.

Hep Dynamics, founded in 2020, provides strategic support on commercialization issues for drug and diagnostics companies in the liver and rare disease markets. Hep Dynamics specializes in devising innovative strategies to identify the niches and messages that maximize opportunities for developmental products and helping clients identify key activities to realize these opportunities. Also, Hep Dynamics sponsors Surfing the NASH Tsunami, a weekly podcast in which a panel of experts discusses commercial developments and challenges in the global NASH market.

Advance Notification

We send out emails to notify our followers before we post on social media, and often it's before your podcast app knows!